Boosting antibody responses by targeting antigens to dendritic cells

Irina Caminschi, Ken Shortman

Research output: Contribution to journalReview ArticleResearchpeer-review

57 Citations (Scopus)


Delivering antigens directly to dendritic cells (DCs) in situ, by injecting antigens coupled to antibodies specific for DC surface molecules, is a promising strategy for enhancing vaccine efficacy. Enhanced cytotoxic T cell responses are obtained if an adjuvant is co-administered to activate the DC. Such DC targeting is also effective at enhancing humoral immunity, via the generation of T follicular helper cells. Depending on the DC surface molecule targeted, antibody production can be enhanced even in the absence of adjuvants. In the case of Clec9A as the DC surface target, enhanced antibody production is a consequence of the DC-restricted expression of the target molecule. Few other cells absorb the antigen-antibody construct, therefore, it persists in the bloodstream, allowing sustained antigen presentation, even by non-activated DCs.

Original languageEnglish
Pages (from-to)71-77
Number of pages7
JournalTrends in Immunology
Issue number2
Publication statusPublished - Feb 2012
Externally publishedYes

Cite this